Biotech News

TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026

TG Therapeutics (TGTX)TG TherapeuticsClinical readout

Late-breaking oral presentation will highlight initial clinical results evaluating azer-cel, an allogeneic “off-the-shelf” CD19-directed CAR T-cell therapy, in patients with progressive multiple sclerosis Additional presentations include Phase 3 ENHANCE data supporting the investigational BRIUMVI

Related news

TG Therapeutics

B-Cell-Directed Therapies TG Therapeutics develops and commercializes therapies targeting B cells in multiple sclerosis and other autoimmune diseases. Its portfolio combines an approved anti-CD20 antibody with alternative formulations and an allogeneic cell-therapy program. BRIUMVI BRIUMVI, or ublituximab, is a glycoengineered CD20...

Recent company news

Stock data

Close
64.88 USD
Market cap
5.61B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States